Q linea

Q linea EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Q linea (QLINEA.ST) as of Nov 3, 2026 is -1.16. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -3.07 — a change of -62.14% (higher).

EV/FCF

-1.16

YoY

-62.14%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Q linea is 2025 -1.16 . EV/FCF (Enterprise Value to Free Cash Flow) of Q linea was 2024 -3.07 . It decreases by -62.14% higher compared to the previous year.

The Q linea EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
0.44 SEK
Jan 1, 2019
-1.37 SEK
Jan 1, 2020
-0.57 SEK
Jan 1, 2021
-1.13 SEK
Jan 1, 2022
-1.48 SEK
Jan 1, 2023
-1.64 SEK
Jan 1, 2024
-3.07 SEK
Jan 1, 2025
-1.16 SEK
The Q linea EV/FCF history
YEAREV/FCFYoY
-1.16-62.14%
-3.07+87.20%
-1.64+10.45%
-1.48+31.35%
-1.13+98.24%
-0.57-58.51%
-1.37-414.92%
0.44-106.28%
-6.94-15.47%
-8.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

EV/FCF (Enterprise Value to Free Cash Flow) of Q linea is -1.16 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Q linea changed from -3.07 to -1.16, representing a -62.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Q linea since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Q linea with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Q linea

All Key Metrics — Q linea